

ESTEVE signs a binding offer to acquire HRA Pharma Rare Diseases, a Perrigo Company affiliate

- ESTEVE will increase its rare and severe diseases portfolio with three medicines addressing Cushing's syndrome and Adrenocortical Carcinoma.
- This is a step forward in the company's vision of being an international specialty pharma company.

Barcelona, April 25, 2024 - ESTEVE has signed a binding offer with Perrigo Company plc to acquire Perrigo's HRA Pharma Rare Diseases, a business specialized in rare and ultra-rare diseases, following the information and consultation process with HRA Pharma Works Council in France and subject to the satisfaction of customary closing conditions, including receipt of regulatory approvals.

ESTEVE will increase its portfolio in the rare and severe diseases therapeutic area, adding to its current portfolio three new medicines that address Cushing's syndrome and Adrenocortical Carcinoma: Metopirone, Lysodren, and Ketoconazole HRA.

HRA Pharma Rare Diseases has over 15 years' experience in rare and ultra-rare diseases and is dedicated to bringing the best care and services to people living with rare diseases and committed to supporting healthcare professionals all over the world. With annual Net Revenues in 2023 around €50M, the HRA Pharma Rare Diseases business has a presence in several European countries as well as in the US.

"This transaction aims to advance ESTEVE on the path of covering the unmet patients' needs, in line with ESTEVE's purpose of improving people's lives and is another step towards the company's vision of being an international specialty pharma company", concludes Staffan Schüberg, Chief Executive Officer of ESTEVE.

Patrick Lockwood-Taylor, Perrigo's President and Chief Executive Officer, states: "We are pleased that ESTEVE, with its track record of growth and international footprint, will look to increase global access to these effective treatment options for all those patients in need".

The binding offer is for up to €275 million, consisting of an upfront payment and potential earnout payments.

The closing of the transaction should take place during the third quarter of 2024, following the required works council consultation and subject to customary regulatory approvals.



Perella Weinberg Partners and Clifford Chance served as ESTEVE's lead advisors on this transaction. Morgan Stanley & Co. LLC and Wachtell, Lipton, Rosen & Katz served as Perrigo's lead advisors on this transaction.

About ESTEVE

ESTEVE (www.esteve.com) is a global pharmaceutical company with headquarters in Barcelona. Its purpose is to improve people's lives and, since its founding in 1929, its focus has been providing solutions for unmet medical needs. ESTEVE has an important presence in Europe thanks to its affiliates in Spain, Portugal, Germany, France, UK and Italy and its own production centers dedicated to the development and manufacture of active pharmaceutical ingredients in Spain, Mexico and China, as well as a pharmaceutical plant in Germany.

About Perrigo

Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at www.perrigo.com.

About HRA Pharma Rare Diseases

HRA Pharma Rare Diseases, an affiliate of Perrigo Company plc, is dedicated to bringing the best care and services to people living with rare diseases and is committed to supporting healthcare professionals all over the world. Well established in Europe and in the USA, the company continues to grow and expand its geographical reach worldwide. HRA Pharma Rare Diseases has a portfolio of medicines that address Cushing's syndrome and Adrenocortical Carcinoma (ACC). By partnering with the community, HRA Pharma Rare Diseases is committed to tackling current challenges, enabling global access to treatment, and offering effective options for the long-term management of rare diseases. Its purpose is to improve quality of life and experience of care for patients. HRA Pharma Rare Diseases is confident that through innovative ideas, robust science, and a passionate and highly experienced team, it can elevate the needs of patients living with a rare disease globally. www.hra-pharma-rare-diseases.com.

For more information:

Irene Simón, Head of Global External Communications & ESG, ESTEVE
Tel.+34 934 466 000 – isimon@esteve.com

Gemma Mestre, External & Digital Communications Manager, ESTEVE
Tel.+34 934 466 000 – gmestre@esteve.com

Bradley Joseph, Vice President, Global Investor Relations and Corporate Communications,
Perrigo - Tel. +1 (269) 686-3373 – bradley.joseph@perrigo.com